Articles
-
2 weeks ago |
ascopost.com | Chase Doyle
Postmastectomy radiation therapy may be significantly shortened for many patients planning breast reconstruction, according to data from a large phase III trial (RT CHARM, Alliance A221505).1 Investigators reported that hypofractionated (short-course) radiation therapy was found to be noninferior to conventional fractionation in patients with breast cancer who underwent breast reconstruction after mastectomy.
-
2 weeks ago |
ascopost.com | Chase Doyle
Proton beam therapy and intensity-modulated radiation therapy (IMRT) were found to offer equivalent quality-of-life outcomes for patients with localized prostate cancer, according to data from the PARTIQoL trial. This phase III trial showed no measurable differences between the two approaches in terms of bowel function, urinary symptoms, or sexual function.
-
3 weeks ago |
ascopost.com | Chase Doyle
Current standard chemoradiation therapy remains the most effective treatment for selected patients with human papillomavirus (HPV)-positive oropharyngeal cancer, based on the results of the NRG-HN005 trial. Researchers have halted this large, randomized phase II/III trial after patients in the control arm reached an unprecedented 2-year progression-free survival rate of 98%, setting a new benchmark for treatment efficacy in early-stage, HPV-associated oropharyngeal cancer.
-
1 month ago |
ascopost.com | Chase Doyle
Neoadjuvant therapy that combines chemotherapy, radiotherapy, and the investigational PD-1 inhibitor sintilimab led to a significantly higher pathologic complete response rate in patients with locally advanced esophageal squamous cell carcinoma, according to data presented at the 2025 ASCO Gastrointestinal Cancers Symposium.1 Preliminary results from the multicenter phase III SCIENCE trial conducted in China revealed that neoadjuvant chemoradiotherapy combined with sintilimab achieved a...
-
1 month ago |
ascopost.com | Chase Doyle
The addition of tafasitamab, a CD19 monoclonal antibody, to the commonly used lenalidomide and rituximab backbone significantly improved progression-free survival in patients with relapsed or refractory follicular lymphoma, according to data presented during the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition.1 Primary results of the phase III inMIND trial demonstrated a median progression-free survival of 22.4 months with tafasitamab vs 13.9 months in the placebo arm,...
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →